GH Should I Buy

BofA raised the firm's price target on Guardant Health to $190 from $135 and keeps a Buy rating on the shares. Guardant Health is expected to benefit from recent wins that should unlock incremental volumes across its oncology and screening franchises and support ASP gains into 2H26 and 2027, with a high likelihood of an FY26 guidance increase on the upcoming earnings call and continued outperformance driven by a strong catalyst pipeline and a premium positioning within specialty diagnostics coverage, the analyst tells investors in a research note.